Metis Global Partners LLC Purchases 6,002 Shares of Pfizer Inc. (NYSE:PFE)

Metis Global Partners LLC raised its position in shares of Pfizer Inc. (NYSE:PFE) by 1.9% during the third quarter, HoldingsChannel.com reports. The fund owned 317,965 shares of the biopharmaceutical company’s stock after buying an additional 6,002 shares during the quarter. Metis Global Partners LLC’s holdings in Pfizer were worth $9,202,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Olistico Wealth LLC acquired a new stake in Pfizer during the second quarter worth approximately $25,000. MFA Wealth Advisors LLC bought a new position in shares of Pfizer during the 2nd quarter worth approximately $29,000. Quarry LP acquired a new stake in shares of Pfizer during the 2nd quarter worth approximately $31,000. Financial Connections Group Inc. acquired a new stake in shares of Pfizer during the 2nd quarter worth approximately $34,000. Finally, ESL Trust Services LLC bought a new stake in shares of Pfizer in the 1st quarter valued at $37,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Down 0.1 %

Shares of PFE stock opened at $26.70 on Thursday. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company has a 50 day moving average of $28.76 and a 200-day moving average of $28.67. The firm has a market cap of $151.31 billion, a P/E ratio of 36.11, a PEG ratio of 0.83 and a beta of 0.67.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm’s quarterly revenue was up 31.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.17) EPS. Sell-side analysts anticipate that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 6.29%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.

Insider Activity at Pfizer

In related news, Director Scott Gottlieb purchased 1,000 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The shares were purchased at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 0.06% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on PFE shares. Wells Fargo & Company raised their price target on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and raised their target price for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Citigroup began coverage on Pfizer in a research note on Friday, October 25th. They set a “neutral” rating and a $30.00 price target on the stock. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Finally, UBS Group upped their target price on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Eight research analysts have rated the stock with a hold rating, five have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $33.58.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.